Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News |  Recently released market study: Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2012Fast Market Research recommends "Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2012" from Global Markets Direct, now available
By: Fast Market Research, Inc. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Progenics Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Progenics Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team. Scope * Progenics Pharmaceuticals, Inc. - Brief Progenics Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries. * Review of current pipeline of Progenics Pharmaceuticals, Inc. human therapeutic division. * Overview of pipeline therapeutics across various therapy areas. * Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. * Product profiles for late stage and clinical stage products of Progenics Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. * Recent updates of the Progenics Pharmaceuticals, Inc.'s pipeline in the last quarter. * Key discontinued and dormant projects. * Latest news and deals relating to the products. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Reasons to buy * Evaluate Progenics Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline. * Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus. * Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. * Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. * Exploit collaboration and partnership opportunities with Progenics Pharmaceuticals, Inc.. * Avoid Intellectual Property Rights related issues. * Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas. Partial Table of Contents: Table of Contents Table of Contents List of Tables List of Figures Progenics Pharmaceuticals, Inc. Snapshot Progenics Pharmaceuticals, Inc. Overview Key Information Key Facts Progenics Pharmaceuticals, Inc. - Research and Development Overview Key Therapeutic Areas Progenics Pharmaceuticals, Inc. - Pipeline Review Pipeline Products by Stage of Development Pipeline Products - Monotherapy Progenics Pharmaceuticals, Inc. - Pipeline Products Glance Progenics Pharmaceuticals, Inc. - Late Stage Pipeline Registration Filed Products/Combination Treatment Modalities Phase III Products/Combination Treatment Modalities Progenics Pharmaceuticals, Inc. Clinical Stage Pipeline Products Phase II Products/Combination Treatment Modalities Phase I Products/Combination Treatment Modalities Progenics Pharmaceuticals, Inc. - Early Stage Pipeline Products Pre-Clinical Products/Combination Treatment Modalities Progenics Pharmaceuticals, Inc. - Drug Profiles methylnaltrexone bromide Product Description Mechanism of Action R&D Progress Multiplex PI3K Inhibitors Product Description Mechanism of Action R&D Progress PSMA ADC Product Description Mechanism of Action R&D Progress Relistor Product Description Mechanism of Action R&D Progress Progenics Pharmaceuticals, Inc. - Pipeline Products by Route of Administration Progenics Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates Progenics Pharmaceuticals, Inc. - Dormant Projects Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products Discontinued Pipeline Product Profiles Clostridium Difficile Antibodies HCV-Entry Inhibitor PRO-140 PRO-206 PSMA VRP Vaccine Progenics Pharmaceuticals, Inc. - Company Statement Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries Head Office Other Locations & Subsidiaries Progenics Pharmaceuticals, Inc., Recent Developments Progenics Pharmaceuticals, Inc.- Press Release Jul 27, 2012: Salix Pharma And Progenics Pharma Receive Complete Response Letter From FDA For Relistor sNDA Apr 25, 2012: Salix And Progenics Announce FDA Extension Of Relistor sNDA Goal Date Oct 14, 2009: Progenics Regains Worldwide Rights to Relistor Franchise Aug 04, 2009: New Delivery System for Relistor in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval Jun 08, 2009: Progenics Provides Update On Hepatitis C Program Feb 10, 2009: Progenics Selects Subcutaneous Form Of PRO 140, A Novel HIV Antibody Therapy, For Further Development Financial Deals Landscape Progenics Pharmaceuticals, Inc., Deals Summary Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details Partnerships Progenics Pharma Extends Its Commercialization Agreement With Wyeth Pharma Progenics Pharma Enters Into Agreement With Seattle Genetics Licensing Agreements Salix Pharma Enters Into Licensing Agreement With Progenics Pharma For Relistor Ono Pharma Enters Into Licensing Agreement With Progenics Pharma Equity Offering Progenics Pharma Files Registration Statement For $100 Million Progenics Pharma Completes Public Offering Of $60 Million Asset Transactions Full Table of Contents is available at: -- http://www.fastmr.com/ About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number